Feuerstein: FDA Raises Safety Questions on Talon Therapeutic's Drug

Notable biotech analyst Adam Feuerstein

on Monday about Talon Therapeutics

and how the FDA rose questions regarding safety about Marqibo-associated peripheral neuropathy. He said via Twitter, "$TLON - FDA raises safety questions about Marqibo-associated peripheral neuropathy, notes 15 patients died on treatment". Currently, shares of Talon are trading up about 2% on the session at $0.99 per share.